The company’s recently appointed CEO Michelle Gallaher said: “The past few weeks have been spent researching, designing and trialling a number of new technology and service concepts to address the high value biopharma and healthcare market.

“There is virtually no healthcare, diagnostic or biopharma organisation in the world that is not gearing up to incorporate AI, digital and data.

“This is a very exciting time as the global sector is developing at an extremely rapid pace and because of the leadership position of The Social Science (TSS), our knowledge of the life sciences and health markets and our digital platforms we are very well placed to compete.

TSS is a specialist social media marketing agency co-founded by Gallaher that was acquired by ShareRoot in April 2018.

Optimising revenue-generating areas of business

A key near-term priority for the company has been to optimise the revenue generating areas of the business, improve operational efficiencies and consolidate resources to conserve cash.

The outcome of the past month has been a reduction in overall running costs, more efficient company operations, redefined focus and a strategic direction for the company in the growing digital healthcare industry.

Gallaher added: “At this point in time every dollar counts and we have to ensure we employ every cent toward generating revenue or generating value – no exceptions.”

Quick facts: Opyl Ltd

Price: 0.145 AUD

ASX:OPL

Market: ASX

Market Cap: $4.29 m

Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...